1.
Open Forum Infect Dis
; 11(2): ofad673, 2024 Feb.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38379566
RESUMEN
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.